| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Ginkgolide C (BN-52022) is a naturally occuring product isolated from Ginko and a GABA-A receptor, α-1 GlyR, and PAF receptor antagonist. It suppresses production of TxA2 to inhibit platelet aggregation and inhibits formation of superoxide and hydroxyl radicals.
| ln Vitro |
After a 24-hour treatment, 3T3-L1 cells' adipogenesis was inhibited by ginkgolide C (3-100 μM), but its viability was unaffected. When compared to the control group, ginkgolide C (10-100 μM) dramatically reduced lipid accumulation and increased glycerol release in 3T3-L1 adipocytes. In differentiated 3T3-L1 adipocytes, ginkgolide C inhibits the expression of PPAR-α and PPAR-γ and decreases the expression of C/EBPα, C/EBPβ, and SREBP-1c. Furthermore, in differentiated 3T3-L1 adipocytes, Ginkgolide C (3-100 μM) dose-dependently inhibits the expression of mRNA and adipogenesis-related proteins (FAS, LPL, and aP2). Additionally, in a concentration-dependent manner, ginkgolide C (3-100 μM) increases the phosphorylation of AMPKα and ACC-1 and significantly promotes the production of Sirt1 [1]. In a dose-dependent manner, ginkgolide C (1, 10, 50, 100, and 500 mM) dramatically inhibited the rat platelet aggregation induced by collagen (10 mg/mL). In collagen-stimulated platelets, ginkgolide C (50, 100 mM) induces the formation of activated MMP-9 (86 kDa) from MMP-9 precursor (92 kDa) [2].
|
|---|---|
| References |
[1]. Liou CJ, et al. Ginkgolide C Suppresses Adipogenesis in 3T3-L1 Adipocytes via the AMPK Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:298635.
[2]. Ginkgolide C, et al. Ginkgolide C inhibits platelet aggregation in cAMP- and cGMP-dependent manner by activating MMP-9. Biol Pharm Bull. 2007 Dec;30(12):2340-4 |
| Molecular Formula |
C20H24O11
|
|---|---|
| Molecular Weight |
440.4
|
| Exact Mass |
440.1319
|
| CAS # |
15291-76-6
|
| Related CAS # |
15291-76-6
|
| SMILES |
O1[C@@]2([H])[C@@]3([C@]([H])(C(=O)O2)O)[C@]([H])(C(C)(C)C)[C@H]([C@]2([H])[C@@]43[C@@H]([C@@]3([H])[C@]([C@H](C)C(=O)O3)([C@]14C(=O)O2)O)O)O
|
| InChi Key |
AMOGMTLMADGEOQ-DTDWCABLSA-N
|
| InChi Code |
InChI=1S/C20H24O11/c1-5-12(24)28-11-8(22)18-10-6(21)7(16(2,3)4)17(18)9(23)13(25)30-15(17)31-20(18,14(26)29-10)19(5,11)27/h5-11,15,21-23,27H,1-4H3/t5-,6-,7+,8+,9+,10-,11+,15+,17+,18-,19-,20-/m1/s1; SMILES: C[C@@H]1C(O[C@H]2[C@@H]([C@]34[C@@H]5OC([C@@]3([C@@]12O)O[C@@H]6OC([C@@H]([C@]46[C@H](C(C)(C)C)[C@H]5O)O)=O)=O)O)=O
|
| Chemical Name |
Ginkgolide A, 1,7-dihydroxy-, (1alpha,7beta)-
|
| Synonyms |
BN-52022; BN52022; BN 52022; Ginkgolide C
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~567.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2707 mL | 11.3533 mL | 22.7066 mL | |
| 5 mM | 0.4541 mL | 2.2707 mL | 4.5413 mL | |
| 10 mM | 0.2271 mL | 1.1353 mL | 2.2707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA